Cancer patients will benefit from a £20 million investment that will bring a new state-of-the-art diagnostic and treatment centre to Surrey. Royal Surrey NHS Foundation Trust is working with specialist oncology group GenesisCare to provide the new facility which is expected to open in late 2021.

Eligible NHS patients and staff will have access to some of the most recent developments as a result of this partnership, including a new Magnetic Resonance Linear Accelerator (MR Linac).

The MR Linac delivers highly precise radiation to tumours while also imaging in real time. It is hoped that this will advance treatments for patients with prostate, pancreatic, lung and liver cancers.

While continuing to deliver world leading treatments and high quality care to NHS cancer patients across the South East of England, Royal Surrey will be the third NHS trust nationally to offer MR Linac treatment to NHS patients.

Dr Robert Laing, Consultant Clinical Oncologist at Royal Surrey, said: “This is an important step forward that will allow us to treat even more patients and offer the very latest in radiotherapy.

“I am looking forward to offering new training programmes to build our hospital’s expertise in these new technologies to a wider number of clinicians.

“Gaining access and experience to the latest leading technologies and equipment that are currently limited in their availability in the UK puts innovation where it matters most – focused on treating more patients more effectively.”

Joe Mills, Director of Strategy at Royal Surrey, said: “Royal Surrey is proud to be a tertiary cancer centre serving a population of two million patients across the South East of England and our work will continue to evolve within our collaboration with GenesisCare. This partnership will set new standards for how the NHS and private care initiatives can and will support innovation to improve health services for patients.”

  • New test will help determine the risk of breast cancer returning
    Breast cancer patients can discover the likelihood of their disease returning in the next 10 years, thanks to a genetic test being offered by scientists in Surrey.

    The investigation offered by clinical scientists at Royal Surrey County Hospital allows for the examination of the individual genetic make-up of breast tumours to determine the probability of disease recurrence. They are measuring the levels of certain genetic material present in the tumour which may influence a patient’s chances of survival and make relapse more likely. Royal Surrey’s Molecular Diagnostic Department is the only site in the UK offering this test to NHS patients.